Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-06-2021 | Schizophrenia | Original Paper

Genetic risks of schizophrenia identified in a matched case–control study

Authors: Kengo Oishi, Tomihisa Niitsu, Nobuhisa Kanahara, Yasunori Sato, Yoshimi Iwayama, Tomoko Toyota, Tasuku Hashimoto, Tsuyoshi Sasaki, Masayuki Takase, Akihiro Shiina, Takeo Yoshikawa, Masaomi Iyo

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2021

Abstract

It has been suggested that dopaminergic neurotransmission plays important roles for the psychotic symptoms and probably etiology of schizophrenia. In our recent preliminary study, we demonstrated that the specific allele combinations of dopamine-related functional single nucleotide polymorphisms (SNPs), rs10770141, rs4680, and rs1800497 could indicate risks for schizophrenia. The present validation study involved a total of 2542 individuals who were age- and sex-matched in a propensity score matching analysis, and the results supported the statistical significances of the proposed genetic risks described in our previous reports. The estimated odds ratios were 1.24 (95% CI 1.06–1.45, p < 0.001) for rs4680, 1.73 (95% CI 1.47–2.02, p < 0.0001) for rs1800497, and 1.79 (95% CI 1.35–2.36, p < 0.0001) for rs10770141. A significant relationship was also revealed among these three polymorphisms and schizophrenia, with corresponding coefficients (p < 0.0001). In this study, we also present a new scoring model for the identification of individuals with the disease risks. Using the cut-off value of 2, our model exhibited sensitivity for almost two-thirds of all of the schizophrenia patients: odds ratio 1.87, 95% CI 1.59–2.19, p < 0.0001. In conclusion, we identified significant associations of dopamine-related genetic combinations with schizophrenia. These findings suggest that some types of dopaminergic neurotransmission play important roles for development of schizophrenia, and this type of approach may also be applicable for other multifactorial diseases, providing a potent new risk predictor.

Available only for authorised users

Howes OD, McCutcheon R, Owen MJ, Murray R (2017) The role of genes, stress and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20CrossRefPubMed

Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141CrossRefPubMedPubMedCentral

Nimgaonkar VL, Prasad KM, Chowdari KV, Severance EG, Yolken RH (2017) The complement system: A gateway to gene-environment interactions in schizophrenia pathogenesis. Mol Psychiatry 11:1554–1561. https://doi.org/10.1038/mp.2017.151CrossRef

Hilker R, Helenius D, Fagerlund B et al (2018) Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish Twin Register. Biol Psychiatry 83:492–498. https://doi.org/10.1016/j.biopsych.2017.08.017CrossRefPubMed

Agid O, Arenovich T, Sajeev G et al (2011) An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 72:1439–1444CrossRefPubMed

Häfner H, Maurer K, an der Heiden W (2013) ABC Schizophrenia study: an overview of results since 1996. Soc Psychiatry Psychiatr Epidemiol 48:1021–1031. https://doi.org/10.1007/s00127-013-0700-4CrossRefPubMed

Li R, Ma X, Wang G, Yang J, Wang C (2016) Why sex differences in schizophrenia? J Transl Neurosci (Beijing) 1:37–42

Mistry S, Harrison JR, Smith DJ, Escott-Price V, Zammit S (2017) The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: systematic review. Schizophr Res. https://doi.org/10.1016/j.schres.2017.10.037CrossRefPubMed

Goldstein JM, Cherkerzian S, Tsuang MT, Petryshen TL (2013) Sex differences in the genetic risk for schizophrenia: History of the evidence for sex-specific and sex-dependent effects. Am J Med Genet B Neuropsychiatr Genet 162B:698–710. https://doi.org/10.1002/ajmg.b.32159CrossRefPubMed

10.

Escamilla R, Camarena B, Saracco-Alvarez R, Fresán A, Hernández S, Aguilar-García A (2018) Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr Dis Treat 14:2981–2987. https://doi.org/10.2147/NDT.S176455CrossRefPubMedPubMedCentral

11.

Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012) Dopamine synthesis 127 capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169(128):1203–1210CrossRefPubMed

12.

Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A, Harrison PJ (2019) Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol Psychiatry 86(8):608–620CrossRefPubMed

13.

Chouinard G, Jones BD (1978) Schizophrenia as dopamine-deficiency disease. Lancet 2:99–100 (PMID: 78321)CrossRefPubMed

14.

Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M (2017) Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 86:189–219. https://doi.org/10.1159/000477313CrossRefPubMed

15.

Kane JM, Agid O, Baldwin ML et al (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. https://doi.org/10.4088/jcp.18com12123CrossRefPubMed

16.

Iyo M, Tadokoro S, Kanahara N et al (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398–404CrossRefPubMed

17.

Takase M, Kanahara N, Oda Y, Niitsu T, Watanabe H, Iyo M (2017) The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia. Schizophr Res 190:182–183CrossRefPubMed

18.

Oishi K, Kanahara N, Takase M et al (2018) Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia. PLoS One 13(e0207133):18

19.

Oishi K, Iyo M, Niitsu T, Takase M, Sato Y, Kanahara N (2020) Genetic combination risk for schizophrenia. Schizophr Res 215:473–474. https://doi.org/10.1016/j.schres.2019.08.021CrossRefPubMed

20.

Horiguchi M, Ohi K, Hashimoto R et al (2014) Functional polymorphism (C-824T) of the tyrosine hydroxylase gene affects IQ in schizophrenia. Psychiatry Clin Neurosci 68:456–462. https://doi.org/10.1111/pcn.12157CrossRefPubMed

21.

Weinshilboum RM, Otterness DM, Szumlanski C (1999) Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19–52. https://doi.org/10.1146/annurev.pharmtox.39.1.19CrossRefPubMed

22.

Pohjalainen T, Rinne JO, Någren K et al (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3:256–260CrossRefPubMed

23.

Steel Z, Marnane C, Iranpour C et al (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol 43:476–493CrossRefPubMedPubMedCentral

24.

Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB (2007) Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry 20:359–364. https://doi.org/10.1097/YCO.0b013e32816ebc8cCrossRefPubMedPubMedCentral

25.

Yamaguchi-Kabata Y, Nakazono K, Takahashi A et al (2008) Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet 83:445–456. https://doi.org/10.1016/j.ajhg.2008.08.019CrossRefPubMedPubMedCentral

26.

Yamada K, Iwayama K, Hattori E et al (2011) Genome-wide association study of schizophrenia in Japanese population. PLoS One 6:e20468CrossRefPubMedPubMedCentral

27.

Hoogendoorn ML, Bakker SC, Schnack HG et al (2005) No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am J Med Genet B Neuropsychiatr Genet 134B:6–9CrossRefPubMed

28.

González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, López-Narváez ML, Tovilla-Zárate CA, Fresan A (2016) The role of a catechol-O-methyltransferase (COMT) Val158Met genetic polymorphism in schizophrenia: a systematic review and updated meta-analysis on 32,816 subjects. Neuromol Med 18:216–231CrossRef

29.

Pelka-Wysiecka J, Wronski M, Jasiewicz A et al (2013) BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep 65:1185–1193CrossRefPubMed

30.

Yao J, Pan YQ, Ding M, Pang H, Wang BJ (2015) Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B:1–13. https://doi.org/10.1002/ajmg.b.32281.ReviewCrossRefPubMed

31.

González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE et al (2016) The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis. Behav Brain Funct 12:29CrossRefPubMedPubMedCentral

32.

Laakso A, Pohjalainen T, Bergman J et al (2005) The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal l-amino acid decarboxylase in healthy subjects. Pharmacogenet Genom 15:387–391CrossRef

33.

Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Männistö PT (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27:10196–10209CrossRefPubMedPubMedCentral

34.

Matsumoto M, Weickert CS, Beltaifa S et al (2003) Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 28:1521–1530CrossRefPubMed

35.

Liu C, Kanazawa T, Tian Y, Mohamed Saini S, Mancuso S et al (2019) The schizophrenia genetics knowledgebase: a comprehensive update of findings from candidate gene studies. Transl Psychiatry 9(1):205. https://doi.org/10.1038/s41398-019-0532-4CrossRefPubMedPubMedCentral

36.

Misiak B, Stramecki F, Gawęda Ł, Prochwicz K, Sąsiadek MM, Moustafa AA et al (2018) Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Mol Neurobiol 55:5075–5100. https://doi.org/10.1007/s12035-017-0708-yCrossRefPubMed

37.

Swathy B, Banerjee M (2017) Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy. Epigenomics 9:721–736CrossRefPubMed

38.

Fusar-Poli P, Tantardini M, De Simone S et al (2017) Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 40:65–75CrossRefPubMed

Title: Genetic risks of schizophrenia identified in a matched case–control study
Authors: Kengo Oishi
Tomihisa Niitsu
Nobuhisa Kanahara
Yasunori Sato
Yoshimi Iwayama
Tomoko Toyota
Tasuku Hashimoto
Tsuyoshi Sasaki
Masayuki Takase
Akihiro Shiina
Takeo Yoshikawa
Masaomi Iyo
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keyword: Schizophrenia
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2021
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-020-01158-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic risks of schizophrenia identified in a matched case–control study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

White matter microstructure in schizophrenia patients with a history of violence

The network structure of schizotypy in the general population

Altered risky decision making in patients with early non-affective psychosis

Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia

Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study

Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia